Entrada Therapeutics, Inc.
TRDA
$6.09
-$0.70-10.31%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -90.51% | -45.03% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -90.51% | -45.03% | |||
| Cost of Revenue | 18.09% | -3.99% | |||
| Gross Profit | -211.97% | -388.48% | |||
| SG&A Expenses | 6.31% | 4.21% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 15.23% | -2.12% | |||
| Operating Income | -115.00% | -271.40% | |||
| Income Before Tax | -147.42% | -2,247.63% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -148.45% | -1,633.95% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -148.45% | -1,633.95% | |||
| EBIT | -115.00% | -271.40% | |||
| EBITDA | -119.80% | -327.57% | |||
| EPS Basic | -146.85% | -1,624.91% | |||
| Normalized Basic EPS | -145.83% | -2,236.28% | |||
| EPS Diluted | -146.85% | -2,160.49% | |||
| Normalized Diluted EPS | -145.83% | -2,367.29% | |||
| Average Basic Shares Outstanding | 0.65% | 0.57% | |||
| Average Diluted Shares Outstanding | 0.65% | -4.59% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||